WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.

Faculty

• 

• William Herrington, MD, FRCP

  Associate Professor
  MRC Population Health Research Unit
  University of Oxford
  Oxford, United Kingdom

  Disclosures

  William Herrington, MD, FRCP, has the following relevant financial relationships:
  Research funding from: Boehringer Ingelheim; Eli Lilly and Company

• 

• Natalie Staplin, PhD

  Associate Professor
  Senior Statistician
  MRC Population Health Research Unit
  University of Oxford
  Oxford, United Kingdom

  Disclosures

  Natalie Staplin, PhD, has the following relevant financial relationships:
  Research funding from: Boehringer Ingelheim; Eli Lilly and Company; Novo Nordisk

• 

• David Cherney, MD, PhD

  Professor of Medicine
  University of Toronto
  Clinician Scientist
  Division of Nephrology, UHN
  Toronto, Canada

  Disclosures

  David Cherney, MD, PhD, has the following relevant financial relationships:
  Consultant or advisor for: AbbVie; AstraZeneca; Bayer; Boehringer Ingelheim-Lilly; Bristol Myers Squibb; CSL Behring; Gilead Sciences; Janssen; Lexicon Pharmaceuticals; Maze Therapeutics; Merck; Mitsubishi-Tanabe; Novartis; Novo Nordisk; Otsuka Pharmaceutical; Prometic Life Sciences Inc. (now, Limial BioSciences); Youngene Therapeutics
  Research funding from: AstraZeneca; Boehringer Ingelheim-Lilly; CSL Behring; Janssen; Merck; Novo Nordisk; Sanofi

• 

• Susanne Nicholas, MD, MPH, PhD

  Professor of Medicine
  David Geffen School of Medicine
  University of California
  Los Angeles, California, United States

  Disclosures

  Susanne Nicholas, MD, MPH, PhD, has the following relevant financial relationships:
  Consultant or advisor for: AstraZeneca; Bayer; Boehringer-Ingelheim-Lilly; Janssen
  Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim-Lilly
  Research funding from: Bayer; Goldfinch Bio; Travere Therapeutics

• 

• Christoph Wanner, MD

  Professor of Medicine
  University of Würzburg
  Würzburg, Germany

  Disclosures

  Christoph Wanner, MD, has the following relevant financial relationships:
  Consultant or advisor for: AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline
  Speaker or member of speakers bureau for: Bayer; Boehringer Ingelheim; Eli Lilly and Company; Fresenius Medical Care; GlaxoSmithKline

Editor

• Rita Moreira Da Silva, PhD, MA, PharmD

  Medical Education Director, WebMD Global, LLC 

  Disclosures

  Rita Moreira Da Silva, PhD, MA, PharmD, has no relevant financial relationships.  

Compliance Reviewer

• Lisa Simani, APRN, MS, ACNP

  Associate Director, Accreditation and Compliance

  Disclosures

  Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.